• MJHLS Brand Logo

© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

Infographic: Adalimumab Approvals in the United States and European Union

Competition for the $16 billion market for Humira is heating up with new approvals for adalimumab biosimilars in the United States and European Union.

Competition for the $16 billion market for Humira is heating up with new approvals for adalimumab biosimilars in the United States and European Union.

Related Content:

BusinessRegulatoryRheumatology
Biosimilars Rheumatology Roundup: June 2025
Adalimumab Double Take: The Unexpected Return to Reference Humira
Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles